27 search results for: comorbidities
The Role of Type 2 Inflammation in Multiple Disease Trajectories
How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.
GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD
Drs. Stephen I. Rennard and Igor Barjaktarevic discuss the diverse clinical aspects of COPD, emphasizing the role of inflammation and the importance of recognizing the heterogeneity of COPD.
The Benefits of Early Intervention in AD: More Than Skin Deep
Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.
Disease Modification Concepts in AD
Dr. Ramien explores the concept of disease modification in AD focusing on disease control, and the prevention or slowing of development of atopic comorbidities.
Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.
The Burden of AD: More Than Skin Deep
Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.
ADVENT at WCPD 2025
The ADVENT symposium at the 15th World Congress of Pediatric Dermatology (WCPD) will focus on discussions around disease modification in atopic dermatitis (AD) in three main topic areas: restoring the skin barrier, reducing non-atopic comorbidities, and stopping the atopic march in pediatric patients with AD aged 6 months to 11 years.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Barrier Breakdown: The Role of Type 2 Inflammation in AD and Atopic Sensitization
Dr. Jeff Yu presents the clinical presentation of pediatric AD and highlights how type 2 inflammation contributes to symptoms and development of atopic comorbidities such as food allergy and asthma at PeDRA 2025
Beyond the Skin: Cumulative Disease Burden in Children With Atopic Dermatitis
Dr. Lara Wine Lee discusses the concept of cumulative life course impairment in AD, focusing on non-atopic comorbidities like vertical growth deficits and mental health impairment and how these might be preventable with early intervention at PeDRA 2025.
Unmet Needs and Management Challenges in Bullous Pemphigoid (BP)
Join Dr. Victoria Werth as she shares the unmet needs and management challenges experienced by patients with bullous pemphigoid (BP), including physical, mental, socioeconomic, and treatment-related burdens. She expands on the comorbidities and increased mortality rates these patients may face.
